1. Infinity Pharmaceuticals, Inc. (63 from 108 patents)

2. Ikena Oncology, Inc. (15 from 15 patents)

3. Infinity Discovery, Inc. (11 from 12 patents)

4. Biogen, Incorporated (9 from 130 patents)

5. Cyteir Therapeutics, Inc. (6 from 8 patents)

6. Sanofi-a Ventis Deutschland Gmbh (2 from 1,827 patents)

7. Other (1 from 832,680 patents)

8. Millennium Pharmaceuticals Limited (1 from 850 patents)

9. Aventis Pharma Deutschland, Gmbh (1 from 330 patents)

10. Biogen Idec Ma Inc. (1 from 216 patents)

11. Askat Inc. (1 from 14 patents)

12. Syntonix Pharmaceuticals, Inc. (1 from 14 patents)

13. Biogen Idec Hemophilia Inc. (1 from 5 patents)

14. Kyn Therapeutics (1 from 1 patent)

15. The Johns Hopkins University (3,682 patents)

1. 12459895 - MEK inhibitors and uses thereof

2. 12295962 - Polymorphic compounds and uses thereof

3. 12162884 - Solid forms of (R)-N-(2-(5-fluoropyridin-3-yl)-8-isopropylpyrazolo[1,5-a] [1,3,5]triazin-4-yl)-2,3,4,9-tetrahydro-1H-carbazol-3-amine as aryl hydrocarbon receptor (AHR) inhibitors

4. 12152032 - Heterocyclic compounds and uses thereof

5. 12077542 - Indole AHR inhibitors and uses thereof

6. 12064419 - Methods of using RAD51 inhibitors for treatment of pancreatic cancer

7. 12030876 - Aryl hydrocarbon receptor (AHR) agonists and uses thereof

8. 11925651 - TEAD inhibitors and uses thereof

9. 11878958 - MEK inhibitors and uses thereof

10. 11760728 - Tead inhibitors and uses thereof

11. 11608329 - Aryl hydrocarbon receptor (AHR) agonists and uses thereof

12. 11607404 - Combinations of RAD51 and PARP inhibitors

13. 11602527 - Methods of use of cyclopamine analogs

14. 11591339 - Solid forms of (R)-N-(2-(5-fluoropyridin-3-yl)-8-isopropylpyrazolo[ 1,5-a][1,3,5]triazin-4-yl)-2,3,4,9-tetrahydro-1H-carbazol-3-amine maleate as aryl hydrocarbon receptor (AHR) inhibitors

15. 11555026 - AHR inhibitors and uses thereof